Abstract |
Twenty-one evaluable patients with advanced squamous-cell cervical cancer were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly. Nineteen had prior chemotherapy. One patient had a partial response; six had stable disease; 14 had increasing disease; and two were unevaluable for response. There was a single life-threatening toxic episode. Aminothiadiazole used in this dosage and schedule has minimal activity in previously treated cervical carcinoma patients.
|
Authors | R F Asbury, J A Blessing, R Mortel, H D Homesley, J Malfetano |
Journal | American journal of clinical oncology
(Am J Clin Oncol)
Vol. 10
Issue 4
Pg. 299-301
(Aug 1987)
ISSN: 0277-3732 [Print] United States |
PMID | 3618541
(Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Thiadiazoles
- 2-amino-1,3,4-thiadiazole
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Carcinoma, Squamous Cell
(drug therapy)
- Drug Administration Schedule
- Drug Evaluation
- Female
- Humans
- Infusions, Intravenous
- Thiadiazoles
(administration & dosage, adverse effects, therapeutic use)
- Uterine Cervical Neoplasms
(drug therapy)
|